IL302388A - SAP FC fusion proteins and methods of use - Google Patents

SAP FC fusion proteins and methods of use

Info

Publication number
IL302388A
IL302388A IL302388A IL30238823A IL302388A IL 302388 A IL302388 A IL 302388A IL 302388 A IL302388 A IL 302388A IL 30238823 A IL30238823 A IL 30238823A IL 302388 A IL302388 A IL 302388A
Authority
IL
Israel
Prior art keywords
seq
amino acid
fusion protein
acid sequence
sap
Prior art date
Application number
IL302388A
Other languages
English (en)
Hebrew (he)
Original Assignee
Attralus Inc
Univ Tennessee Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attralus Inc, Univ Tennessee Res Found filed Critical Attralus Inc
Publication of IL302388A publication Critical patent/IL302388A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL302388A 2020-11-02 2021-11-01 SAP FC fusion proteins and methods of use IL302388A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108799P 2020-11-02 2020-11-02
US202163153777P 2021-02-25 2021-02-25
PCT/US2021/072168 WO2022094630A1 (en) 2020-11-02 2021-11-01 Sap fc fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
IL302388A true IL302388A (en) 2023-06-01

Family

ID=78771272

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302388A IL302388A (en) 2020-11-02 2021-11-01 SAP FC fusion proteins and methods of use

Country Status (10)

Country Link
US (2) US12161692B2 (enExample)
EP (1) EP4237083A1 (enExample)
JP (1) JP7856264B2 (enExample)
KR (1) KR20230097061A (enExample)
AU (1) AU2021368272A1 (enExample)
BR (1) BR112023008317A2 (enExample)
CA (1) CA3196766A1 (enExample)
IL (1) IL302388A (enExample)
MX (1) MX2023005063A (enExample)
WO (1) WO2022094630A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
BR112023008317A2 (pt) 2020-11-02 2024-02-06 Attralus Inc Proteínas de fusão sap fc e métodos de uso
WO2024153768A1 (en) * 2023-01-20 2024-07-25 Boehringer Ingelheim International Gmbh Il-12 fc fusion proteins

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317120D0 (en) 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
AU2002225772A1 (en) 2000-11-27 2002-06-03 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
US9200079B2 (en) * 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
WO2011119608A1 (en) 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
CN104203981A (zh) 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
WO2013096847A1 (en) 2011-12-21 2013-06-27 Promedior, Inc. Serum amyloid p-antibody fusion proteins
EP3027647A4 (en) 2013-07-31 2017-01-04 Amgen Inc. Stabilization of fc-containing polypeptides
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
US20200148779A1 (en) 2017-05-25 2020-05-14 Bristol-Myers Squibb Company MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
JP2021521273A (ja) 2018-04-12 2021-08-26 メディアファーマ エス．アール．エル． Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用
BR112023008317A2 (pt) 2020-11-02 2024-02-06 Attralus Inc Proteínas de fusão sap fc e métodos de uso

Also Published As

Publication number Publication date
US20220160831A1 (en) 2022-05-26
WO2022094630A1 (en) 2022-05-05
US20250152667A1 (en) 2025-05-15
CA3196766A1 (en) 2022-05-05
AU2021368272A1 (en) 2023-06-08
MX2023005063A (es) 2023-05-12
KR20230097061A (ko) 2023-06-30
JP7856264B2 (ja) 2026-05-11
US12161692B2 (en) 2024-12-10
JP2023550287A (ja) 2023-12-01
BR112023008317A2 (pt) 2024-02-06
AU2021368272A9 (en) 2025-03-13
EP4237083A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
US20250152667A1 (en) Sap fc fusion proteins and methods of use
US12291552B2 (en) Chimeric protein in the treatment of amyloidosis
JP7458327B2 (ja) 血液脳関門移動化合物及びその使用
RU2702553C2 (ru) Новое антитело против tie-2 человека
JP2018511327A (ja) 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン
CA2878640A1 (en) Multivalent heteromultimer scaffold design and constructs
US20230002460A1 (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
CA2891190A1 (en) Aprotinin-derived polypeptide-antibody conjugates
JP2025532806A (ja) Ｇｐｒｃ５ｄ ｔｃｂとｉｍｉｄの併用療法
US20260035433A1 (en) Pd-l1 analog fusion proteins for antigen specific immunotherapy and methods of use
KR20220157910A (ko) Gdf15 변이체 및 glp-1 수용체 작용제를 포함하는 병용 투여용 조성물
US20240082354A1 (en) Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
EA049439B1 (ru) СЛИТЫЕ БЕЛКИ SAP-Fc И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN117120479A (zh) Sap fc融合蛋白及其使用方法
RU2836280C1 (ru) Слитый белок gdf15 длительного действия и содержащая его фармацевтическая композиция
JP2022544401A (ja) Ｔｇｆ－ベータトラップ
HK40073215A (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
WO2025070337A1 (ja) 抗ＭｅｒＴＫアゴニスト抗体、抗ＭｅｒＴＫ二重特異性抗体、及びその使用
JP2025533112A (ja) Ｇｐｒｃ５ｄ ｔｃｂとｃｄ３８抗体との併用療法
JP2025533183A (ja) Ｇｐｒｃ５ｄ ｔｃｂとプロテアソーム阻害剤との併用療法
HK40108366A (en) Methods of using activin receptor type ii signaling inhibitors